FPS
CHRS icon

Fieldpoint Private Securities’s Coherus Oncology CHRS Stock Holding History

Fieldpoint Private Securities’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-45
Closed -$1K – 1519
2022
Q1 		$1K Buy
+45
New +$572 ﹤0.01% 1547
2021
Q2 		– Sell
-65
Closed -$1K – 1563
2021
Q1 		$1K Buy
+65
New +$1.1K ﹤0.01% 1449

Other funds holding CHRS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Fieldpoint Private Securities's CHRS Position: Q2 2022 in Review

Fieldpoint Private Securities sold out of Coherus Oncology (CHRS) in Q2 2022, closing a stake of 45 shares — an estimated $1K sold.

Fieldpoint Private Securities first reported a position in CHRS in Q1 2021 and held it in 2 quarters. The position peaked at $1K in Q1 2022. 176 funds tracked by Wall St. Rank hold CHRS as of Q2 2022.

  • Fieldpoint Private Securities reported no remaining Coherus Oncology position as of Q2 2022 after selling out during the quarter.
  • Fieldpoint Private Securities sold 45 Coherus Oncology shares in Q2 2022, an estimated $1K.
  • Fieldpoint Private Securities first reported a position in Coherus Oncology in Q1 2021 and held it in 2 quarters.
  • Fieldpoint Private Securities's Coherus Oncology position peaked at $1K in Q1 2022.
  • 176 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.